Share this

KN 755 – adverse events management

Reference:

  1. KEYTRUDA USPI.
  2. Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) forUterine Neoplasms V.1.2023. © National Comprehensive Cancer Network, Inc. 2023. All rights reserved. To view themost recent and complete version of the guidelines, go online to NCCN. org. Available at:https://www.nccn.org/professionals/physician_gls/pdf/uterine.pdf
  3. Bartley AN, Hamilton SR, Alsabeh R, et al. Template for reporting results of biomarker testing of specimensfrom patients with carcinoma of the colon and rectum. Arch Pathol Lab Med. 2014;138(2):166–170.
  4. Vilar E, Gruber SB. Microsatellite instability in colorectal cancer—the stable evidence. Nat Rev Clin Oncol.2010;7(3):153–162
  5. Dudley JC, Lin M-T, Le DT, et al. Microsatellite instability as a biomarker for PD-1 blockade. Clin Cancer Res.2016;22(4):813-820

Reference:

  1. KEYTRUDA USPI.
  2. Makker V, Colombo N, Herráez AC, et al. A multicenter, open-label, randomized, phase 3 study to compare theefficacy and safety of lenvatinib in combination with pembrolizumab vs treatment of physician’s choice in patientswith advanced endometrial cancer: Study 309/KEYNOTE-775. Slide deck presented at: Virtual AnnualMeeting on Women’s Cancer; 19–25 March 2021

Reference:

  1. KEYTRUDA USPI.
  2. Makker V, Colombo N, Herráez AC, et al. A multicenter, open-label, randomized, phase 3 study to compare theefficacy and safety of lenvatinib in combination with pembrolizumab vs treatment of physician’s choice in patientswith advanced endometrial cancer: Study 309/KEYNOTE-775. Slide deck presented at: Virtual AnnualMeeting on Women’s Cancer; 19–25 March 2021

Reference:

  1. KEYTRUDA USPI.
  2. Makker V, Colombo N, Herráez AC, et al. A multicenter, open-label, randomized, phase 3 study to compare theefficacy and safety of lenvatinib in combination with pembrolizumab vs treatment of physician’s choice in patientswith advanced endometrial cancer: Study 309/KEYNOTE-775. Slide deck presented at: Virtual AnnualMeeting on Women’s Cancer; 19–25 March 2021

Reference:

  1. KEYTRUDA USPI.
  2. Makker V, Colombo N, Herráez AC, et al. A multicenter, open-label, randomized, phase 3 study to compare the efficacy and safety of lenvatinib in combination with pembrolizumab vs treatment of physician’s choice in patients with advanced endometrial cancer: Study 309/KEYNOTE-775. Slide deck presented at: Virtual Annual Meeting on Women’s Cancer; 19–25 March 2021
Adverse Events
Adverse events Management

Reference:

  1. KEYTRUDA USPI.

Reference:

  1. KEYTRUDA USPI.
  2. LENVIMA Core Data sheet

Reference:

  1. KEYTRUDA USPI.
  2. Concin N, Matias-Guiu X, Vergote I, et al. ESGO/ESTRO/ESP guidelines for the management of patients withendometrial carcinoma. Int J Gynecol Cancer. Published online December 18, 2020. doi:10.1136/ijgc-2020- 002230.

Superior OS
Superior PFS
Superior ORR

Reference:

  1. KEYTRUDA USPI.
  2. Makker V, Colombo N, Herráez AC, et al. A multicenter, open-label, randomized, phase 3 study to compare the efficacy and safety of lenvatinib in combination with pembrolizumab vs treatment of physician’s choice in patients with advanced endometrial cancer: Study 309/KEYNOTE-775. Slide deck presented at: Virtual Annual Meeting on Women’s Cancer; 19–25 March 2021

AE-END-00004 Exp 30 MAY 2025
AE-END-00002 | Exp 20 FEB 2025
BH-END-00001 | Exp 15 FEB 2025